Press

Supermind Platforms, Inc Acquires Psychedelics.com and Closes Pre-Seed Financing

Sep 30 • 3 min read

Supermind Platforms, Inc has raised an undisclosed amount in its pre-seed financing round from angel and institutional investors to build trusted digital access points to psychedelic assisted therapy and mental wellness on its leading domains including Psychedelics.com and Microdosing.com. The initial pre-seed round was closed in July of 2022 allowing Supermind to continue building an expert team of creatives, technologists,…

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting

Sep 30 • 2 min read

Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders. The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 5,073,132, representing 43.57% of the Company’s 11,642,953 outstanding common shares entitled to…

Irwin Naturals Acquiring Ketamine Media

Sep 30 • 3 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) today announced a definitive agreement to purchase all of the issued and outstanding shares of Keta Media, LLC dba Ketamine Media, the nation’s leading growth platform for clinics offering ketamine-assisted therapy. With a global network dedicated to improving patient outcomes, KM has established relationships with clinics…

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

Sep 30 • 3 min read

PharmaTher Holdings Ltd.( OTCQB: PHRRF | CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, today released business highlights and audited financial results for its fiscal year ended May 31, 2022. All amounts in this press release are…

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

Sep 29 • 4 min read

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc. (“Psilo Pharma”), from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner in Portugal (the “Research Partner”). In February 2022, Psyence received an import permit…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441